Sale of Equity Interests in Theravance Respiratory Company, LLC and Discontinued Operations - Summary of TRC's Statement of income and equity Interest (Details) - USD ($) $ in Thousands		3 Months Ended								12 Months Ended
	Jul. 20, 2022	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Assets
Cash and cash equivalents		$ 298,172				$ 89,959				$ 298,172	$ 89,959	$ 81,467
Total assets		607,400				374,819				607,400	374,819
Liabilities and LLC Members' Equity
Total liabilities and shareholders' equity (deficit)		607,400				374,819				607,400	374,819
Revenue:
Total revenue		14,649	$ 12,451	$ 11,050	$ 13,196	14,946	$ 13,194	$ 12,914	$ 14,257	51,346	55,311	71,857
Collaboration revenue
Revenue:
Total revenue										192	11,463	26,464
TRC
Assets
Total assets	$ 72,029					130,971					130,971
Liabilities and LLC Members' Equity
Total liabilities and shareholders' equity (deficit)	72,029					130,971					130,971
Revenue:
Total revenue	72,029										126,688	83,090
General and administrative expenses	332										3,956	2,613
Other income, net	10											38
Changes in fair value of equity and long-term investments, net	(8,884)										(1,541)	1,147
Realized loss on equity and long-term investments	(39,385)
Net Income	23,438										121,191	81,662
TRC | Royalties
Revenue:
Total revenue	72,029										126,688	73,090
TRC | Collaboration revenue
Revenue:
Total revenue												$ 10,000
TRC
Assets
Related party receivables from collaborative arrangements		$ 0				43,500				$ 0	43,500
TRC | TRC
Assets
Cash and cash equivalents	29,309					50,713					50,713
Related party receivables from collaborative arrangements	42,720					42,492					42,492
Prepaid expenses and other current assets						71					71
Equity and long-term investments						37,695					37,695
Liabilities and LLC Members' Equity
Accrued liabilities						252					252
LLC members' equity	$ 72,029					$ 130,719					$ 130,719